| 产品名称 | Quartett C-P015/P-P015 | PTEN (QR042) |
|---|---|
| 目录号 | C-P015/P-P015 |
| 别名 | PTEN |
| 外观 | 见COA |
| 分子量 | |
| CAS | |
| 溶解度 | |
| 存储条件 | 见COA |
| 保存时间 | 见COA |
| 备注1 | |
| 备注2 |
Quartett C-C031/P-C031 | CD31 (QR034)
品名：PTEN (QR042) | Recombinant monoclonal rabbit antibody
货号：C-P015/P-P015
品牌：Quartett
规格：0.1 ml; 0.5 ml; 1 ml; 3 ml; 7 ml; 15 ml
产品描述
| Application | IHC (FFPE) | Host | Rabbit |
| Subclass | IgG | Dilution range | 1:100 – 1:200 |
| Cellular localization | Cytoplasm, nucleus | Control | Endometrial adenocarcinoma |
| Immunogen | Synthetic peptide from human PTEN | ||
Phosphatase and tensin homolog (PTEN) is an important tumor suppressor that inhibits cell growth and increases cellular sensitivity to apoptosis. The phosphatase PTEN metabolizes PIP3, the lipid product of PI3 kinase, and directly antagonizes the activation of the oncogenic PI3K/AKT/mTOR signaling network. Accordingly, loss of function of the PTEN tumor suppressor is one of the most common events observed in a large number of cancers, such as glioblastoma, endometrial carcinoma, melanoma, prostate, colorectal, lung, and breast carcinomas. Furthermore, PTEN mutation causes a variety of hereditary predispositions to cancer. Although the mechanisms by which PTEN function is disrupted are diverse, the most commonly observed events are deletion of a single gene copy of PTEN and gene silencing. This is typically observed in primary and metastatic human cancers with little or no PTEN protein detectable by IHC. The incidence of PTEN loss is highest in aggressive metastatic disease, and this has driven the development of PTEN as a prognostic biomarker, either alone or in combination with other factors, to distinguish indolent tumors from those likely to progress.
